Ocular Therapeutix
OCUL
69 hedge funds and large institutions have $86.5M invested in Ocular Therapeutix in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 11 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
36% more call options, than puts
Call options by funds: $565K | Put options by funds: $416K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.47% less ownership
Funds ownership: 56.1% → 52.63% (-3.5%)
5% less funds holding
Funds holding: 73 → 69 (-4)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
42% less capital invested
Capital invested by funds: $149M → $86.5M (-$62.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SR
Summer Road
West Palm Beach,
Florida
|
+$4.17M |
| 2 |
Man Group
London,
United Kingdom
|
+$3.77M |
| 3 |
BlackRock
New York
|
+$2.76M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$879K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.5M |
| 2 |
Jennison Associates
New York
|
-$3.88M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.76M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.47M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.46M |
OCUL Hedge Fund Activity: Q4 2018 in Review
69 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2018, worth a combined $86.5M — down 42% from $149M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OCUL and 8 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 26 added.
The largest buyer was Summer Road, adding an estimated $4.17M. The largest seller was Opaleye Management, exiting entirely with an estimated $5.5M sold.
- 69 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2018, down from 73 in Q3 2018.
- Funds reported $86.5M of Ocular Therapeutix stock for Q4 2018, down 42% quarter-over-quarter.
- 8 funds opened new Ocular Therapeutix positions in Q4 2018 and 11 closed out, a net change of -3 holders.
- The largest Ocular Therapeutix buyer in Q4 2018 was Summer Road, an estimated $4.17M added.
- The largest Ocular Therapeutix seller in Q4 2018 was Opaleye Management, an estimated $5.5M sold.
Based on aggregated 13F filings for Q4 2018.